STATEMENT ON COVID-19 VACCINATIONS
26 February 2021
COVID-19 has impacted individuals and families across all walks of life. Our neuromuscular community has felt this impact in many ways, including concern for worsening of disease course and respiratory status with infection. Vaccines against COVID-19 are now being adopted and distributed in many countries. With vaccination comes great hope for protection against the virus and a gradual return to “normalcy”. We therefore encourage and recommend all individuals who are able to access the vaccine to do so, as data shows it is safe and effective. Please consult the following links for more information about vaccine safety and effectiveness.
- Doctor—Should I get the COVID‐19 vaccine? Infection and immunization in individuals with neuromuscular disorders
- No Excess Risk for Neurologic Events Observed to Date from COVID-19 Vaccines
- COVID-19 Vaccines and NMDs (from muscular dystrophy Canada)
- MDA COVID-19 resources
- MDA letter to the CDC
- WMS advice on vaccine
- WMS general on COVID
- ERN COVID information
As countries develop plans to roll out their vaccine programs, and necessarily have to adopt strategies with prioritization, we strongly advocate that patients with neuromuscular disorders be considered as a high risk, priority group. We echo and support statements made from organizations around the world calling for prioritization for vaccination for individuals affected with neuromuscular diseases and their care givers. This is because of the potential adverse and dire consequences of contracting COVID in individuals with muscle weakness that can compromise function, particularly leading to respiratory failure, a known concern in neuromuscular patients with respiratory illnesses. Also, at present, vaccination is only approved for individuals over 16 years of age. We strongly encourage testing for safety and efficacy for the pediatric population, as many vulnerable pediatric patient groups will highly benefit from protection by vaccination against COVID.
James Dowling, Chair, on behalf of the TREAT NMD Executive Committee
STATEMENT ON COVID-19
25 March 2020
The COVID-19 outbreak is increasingly impacting countries worldwide, with many undertaking restrictive measures on their citizens to contain the spread of the virus, including recommendations that all those with a rare disease should self-isolate for 12 weeks. As neuromuscular conditions are considered rare diseases, TREAT-NMD highly recommends following the advice of your national authority, and the World Health Organisation. The latest updates from The Association of British Neurologists can be found here, and the latest press release from EURORDIS Rare Diseases Europe can be found here.
TREAT-NMD also recommends that patients, carers and healthcare professionals follow the general advice about Covid-19 and the effect on people with neuromuscular diseases published by the World Muscle Society. We would also like to draw attention to recordings of the World Duchenne Organisation’s weekly online webinars which contain useful tips, advice and recommendations for the Duchenne community.
Please note, any specific individual questions or problems should be discussed with your relevant healthcare professionals.
The TREAT-NMD Network continues to be operational during the COVID-19 outbreak. You can keep up-to-date on our activities through our website and social media channels: sign up to our monthly newsletter here, and follow us on twitter @TREAT_NMD